Cargando…

Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is common in elderly people and is increasing in prevalence. No specific treatment for this condition exists. Coenzyme Q10 (CoQ10) is an essential cofactor for energy production, with reduced levels being noted in HF. Previous studie...

Descripción completa

Detalles Bibliográficos
Autores principales: Samuel, Tal Y., Hasin, Tal, Gotsman, Israel, Weitzman, Tanya, Ben Ivgi, Fanny, Dadon, Ziv, Asher, Elad, Amir, Offer, Glikson, Michael, Alcalai, Ronny, Leibowitz, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885873/
https://www.ncbi.nlm.nih.gov/pubmed/34826125
http://dx.doi.org/10.1007/s40268-021-00372-1
_version_ 1784660538281689088
author Samuel, Tal Y.
Hasin, Tal
Gotsman, Israel
Weitzman, Tanya
Ben Ivgi, Fanny
Dadon, Ziv
Asher, Elad
Amir, Offer
Glikson, Michael
Alcalai, Ronny
Leibowitz, David
author_facet Samuel, Tal Y.
Hasin, Tal
Gotsman, Israel
Weitzman, Tanya
Ben Ivgi, Fanny
Dadon, Ziv
Asher, Elad
Amir, Offer
Glikson, Michael
Alcalai, Ronny
Leibowitz, David
author_sort Samuel, Tal Y.
collection PubMed
description BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is common in elderly people and is increasing in prevalence. No specific treatment for this condition exists. Coenzyme Q10 (CoQ10) is an essential cofactor for energy production, with reduced levels being noted in HF. Previous studies have suggested a possible role for CoQ10 in the treatment of HF. This study examined the effect of CoQ10 supplementation on diastolic function in HFpEF patients. METHODS: We conducted a prospective, randomized, double-blind, placebo-controlled trial including patients aged > 55 years presenting with New York Heart Association class II–IV heart failure symptoms and left ventricular ejection fraction > 50%, with impaired diastolic function. Echocardiography and levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed at baseline and following 4 months of CoQ10 or placebo supplementation. RESULTS: A total of 39 patients were enrolled—19 in the CoQ10 group and 20 in the placebo group. Baseline clinical characteristics were similar between groups, while compliance was high and also similar between the CoQ10 and placebo groups. There was no significant effect of treatment on indices of diastolic function (difference in the lateral E/e' ratio: −0.86 ± 6.57 in the CoQ10 group, +0.18 ± 3.76 in the placebo group; p = 0.561) or on serum NT-proBNP levels (− 72 pg/mL vs. − 42 pg/mL; p = 0.195). CONCLUSIONS: In this pilot trial in elderly patients with HFpEF, treatment with CoQ10 did not significantly affect echocardiographic indices of diastolic function and serum NT-proBNP levels. TRIAL REGISTRATION: This trial was registered in the US National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier: NCT02779634).
format Online
Article
Text
id pubmed-8885873
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-88858732022-03-08 Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial Samuel, Tal Y. Hasin, Tal Gotsman, Israel Weitzman, Tanya Ben Ivgi, Fanny Dadon, Ziv Asher, Elad Amir, Offer Glikson, Michael Alcalai, Ronny Leibowitz, David Drugs R D Original Research Article BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is common in elderly people and is increasing in prevalence. No specific treatment for this condition exists. Coenzyme Q10 (CoQ10) is an essential cofactor for energy production, with reduced levels being noted in HF. Previous studies have suggested a possible role for CoQ10 in the treatment of HF. This study examined the effect of CoQ10 supplementation on diastolic function in HFpEF patients. METHODS: We conducted a prospective, randomized, double-blind, placebo-controlled trial including patients aged > 55 years presenting with New York Heart Association class II–IV heart failure symptoms and left ventricular ejection fraction > 50%, with impaired diastolic function. Echocardiography and levels of serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) were performed at baseline and following 4 months of CoQ10 or placebo supplementation. RESULTS: A total of 39 patients were enrolled—19 in the CoQ10 group and 20 in the placebo group. Baseline clinical characteristics were similar between groups, while compliance was high and also similar between the CoQ10 and placebo groups. There was no significant effect of treatment on indices of diastolic function (difference in the lateral E/e' ratio: −0.86 ± 6.57 in the CoQ10 group, +0.18 ± 3.76 in the placebo group; p = 0.561) or on serum NT-proBNP levels (− 72 pg/mL vs. − 42 pg/mL; p = 0.195). CONCLUSIONS: In this pilot trial in elderly patients with HFpEF, treatment with CoQ10 did not significantly affect echocardiographic indices of diastolic function and serum NT-proBNP levels. TRIAL REGISTRATION: This trial was registered in the US National Institutes of Health Clinical Trials Registry (ClinicalTrials.gov identifier: NCT02779634). Springer International Publishing 2021-11-26 2022-03 /pmc/articles/PMC8885873/ /pubmed/34826125 http://dx.doi.org/10.1007/s40268-021-00372-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Samuel, Tal Y.
Hasin, Tal
Gotsman, Israel
Weitzman, Tanya
Ben Ivgi, Fanny
Dadon, Ziv
Asher, Elad
Amir, Offer
Glikson, Michael
Alcalai, Ronny
Leibowitz, David
Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
title Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
title_full Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
title_fullStr Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
title_full_unstemmed Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
title_short Coenzyme Q10 in the Treatment of Heart Failure with Preserved Ejection Fraction: A Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
title_sort coenzyme q10 in the treatment of heart failure with preserved ejection fraction: a prospective, randomized, double-blind, placebo-controlled trial
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885873/
https://www.ncbi.nlm.nih.gov/pubmed/34826125
http://dx.doi.org/10.1007/s40268-021-00372-1
work_keys_str_mv AT samueltaly coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT hasintal coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT gotsmanisrael coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT weitzmantanya coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT benivgifanny coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT dadonziv coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT asherelad coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT amiroffer coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT gliksonmichael coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT alcalaironny coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial
AT leibowitzdavid coenzymeq10inthetreatmentofheartfailurewithpreservedejectionfractionaprospectiverandomizeddoubleblindplacebocontrolledtrial